

Title Page:

Title:

Influence of Poor Sleep on Cardiovascular Disease-Free Life Expectancy: A Multi-Resource-Based Population Cohort Study

Author names and affiliations:

Bo-Huei Huang, M.Sc.

Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Borja del Pozo Cruz, Ph.D.

Centre for Active and Healthy Ageing, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark

Armando Teixeira-Pinto, Ph.D.

Affiliation: Sydney School of Public Health, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Peter A. Cistulli, Ph.D.

Charles Perkins Centre, Sydney Medical School, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Emmanuel Stamatakis, Ph.D.

Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Corresponding authors information:

Emmanuel Stamatakis, Ph.D.

Hub D17, Charles Perkins Centre L6 West, the University of Sydney, NSW 2006

+61-4-3270-4690

emmanuel.stamatakis@sydney.edu.au

1 **Abstract**

2 Background

3 The complexity of sleep hinders the formulation of sleep guidelines. Recent studies suggest that
4 different unhealthy sleep characteristics jointly increase the risks for cardiovascular disease
5 (CVD). This study aimed to estimate the differences in CVD-free life expectancy between
6 people with different sleep profiles.

7
8 Methods

9 We included 308683 middle-aged adults from the UK Biobank among whom 140181 had
10 primary care data linkage. We used an established composite sleep score comprising self-
11 reported chronotype, duration, insomnia complaints, snoring, and daytime sleepiness to derive
12 three sleep categories: poor, intermediate, and healthy. We also identified three clinical sleep
13 disorders captured by primary care and inpatient records within two years before enrollment in
14 the cohort: insomnia, sleep-related breathing disorders, and other sleep disorders. We estimated
15 sex-specific CVD-free life expectancy with three-state Markov models conditioning on survival
16 at age 40 across different sleep profiles and clinical disorders.

17
18 Results

19 We observed a gradual loss in CVD-free life expectancy toward poor sleep such as, compared
20 with healthy sleepers, poor sleepers lost 1·80 [95% CI 0·96-2·75] and 2·31 [1·46-3·29] CVD-
21 free years in females and males, respectively, while intermediate sleepers lost 0·48 [0·41-0·55]

22 and 0·55 [0·49-0·61] years. Among men, those with clinical insomnia or sleep-related breathing
23 disorders lost CVD-free life by 3·84 [0·61-8·59] or 6·73 [5·31-8·48] years, respectively. Among
24 women, sleep-related breathing disorders or other sleep disorders were associated with 7·32
25 [5·33-10·34] or 1·43 [0·20-3·29] years lost, respectively.

26

27 Conclusions

28 Both self-reported and doctor-diagnosed poor sleep are negatively associated with CVD-free life,
29 especially pronounced in participants with sleep-related breathing disorders.

30

31 **Main Text**

32 **Background**

33 The World Health Organization has recognized sleep as a critical health state and health-related
34 behavior.(1) Although one-fourth of Europeans have insomnia,(2) with very few exceptions,(3)
35 there is very little national guidance on sleep, reflecting the complexity of sleep health as a
36 multi-dimensional behavior(4) as well as the lack of longitudinal evidence base on population-
37 wide effects of poor sleep.(3,5)

38

39 One major difficulty in evaluating the health impacts of sleep is its complexity as a biological
40 process and behavior.(4) Current estimates of optimal nocturnal sleep range in adults is seven to
41 less than nine hours per night,(6,7) with little evidence-based guidance on other health-related
42 sleep characteristics, such as quality and timing.(5,8) While most cohorts fail to capture the
43 multi-dimensional nature of sleep, recent studies have highlighted joint effects of different sleep
44 characteristics with risks for cardiovascular disease (CVD).(8,9) With a composite sleep score
45 comprising chronotype, duration, insomnia complaint, snoring, and daytime sleepiness, Fan et al.
46 found that healthy sleepers had a 35% lower risk of incident CVD than poor sleepers.(9) Using
47 the same set of sleep measures, our previous work further suggested that poor sleepers had a
48 39% higher risk of CVD mortality than healthy sleepers.(8) These findings indicated that a
49 traditional mutually adjusted approach could not capture the multiplicative effects of different
50 sleep characteristics, and the derived individual/independent effect of a single characteristic
51 could be spurious.

52 Compared to ratio-based estimation, years of life lost free of diseases, the difference in disease-
53 free life expectancy between people with different characteristics provides a tangible metric on
54 the burdens of exposures taking both morbidity and mortality into account. Life expectancy is
55 easy to communicate to policymakers, media, and the general population.(10–12) However, no
56 study has used such measures to evaluate the health burden of comprehensive sleep
57 characteristics. Primary care (general practice) records have distinct advantages in capturing
58 incident sleep disorders more comprehensively and objectively.(5)

59

60 To our knowledge, no prior sleep research has used primary care diagnoses to estimate the health
61 burden of the compromised life expectancy of sleep disorders. Therefore, this study aimed to
62 estimate CVD-free years of life lost among people with poor sleep, evaluated by self-report and
63 clinical primary care diagnosis.

64

65 **Methods**

66 **Data Source**

67 We retrieved individual data from the UK Biobank, a population-based prospective cohort that
68 recruited participants in 22 assessment centers throughout England, Wales, and Scotland
69 between 2006 and 2010 (<https://www.ukbiobank.ac.uk/>). Full cohort details can be found
70 elsewhere.(13,14) In brief, more than half a million participants (response rate 6%) aged 40 to 69
71 provided informed consent to enrolment and data linkage to electronic health records. The
72 baseline assessment included self-reported questionnaires, a computer-assisted personal
73 interview, physical examinations, and biological sampling. The UK Biobank keeps removing all

74 records of dropping out participants, so retrieving loss of follow-up is inapplicable. By the time
75 we conducted the current study (October 2021), there were 502,459 participants with data
76 available. The National Health Service and the National Research Ethics Service have approved
77 the UK Biobank (Ref. 11/NW/0382).

78

79 **Electronic Health Records**

80 The UK Biobank repository accesses national registered data on hospital inpatient diagnoses and
81 death for all participants across the UK through the National Health Service (NHS). The NHS
82 encoded records with the International Classification of Diseases (ICD), of which both the Ninth
83 Revision (ICD-9) and the Tenth Revision (ICD-10) were available for the inpatient records,
84 while only ICD-10 was applied to the death registry. Inpatient records were availed from 1981
85 onwards. Both registries were censored up to March 2021, with slight differences between
86 countries (**appendix pp 2**).

87

88 Primary care data on clinical events and prescriptions covered 227834 participants. Primary care
89 clinical events were coded with Read codes version 2 (Read v2) or Clinical Terms Version 3
90 (CTV3), while prescriptions were mainly coded with Read v2, British National Formulary
91 (BNF), or Dictionary of Medicines and Devices (dm+d). Further details of primary care data
92 sources, cleaning, and harmonization are provided in **appendix pp 2, 19**. The primary care was
93 censored to September 2018, with data availability varied between participants and was
94 determined by the registration date with a primary care practice.

95

96 **CVD Incidence and All-Cause Mortality**

97 We identified the incidence of hospital inpatient disease events based on ICD-9 and ICD-10:
98 CVD (I01 to I09, I11, I13, I21 to I25, I27, I3, I4, I50, I51, I6, I7, I80 to I84, I87 to I9,
99 R54).(10,15) The corresponding ICD-9 was provided in **appendix pp 3**. The date of events and
100 death were retrieved from the NHS electronic health records described above.

101

102 **Sleep Exposure**

103 As part of the baseline questionnaire, participants reported five sleep characteristics, based on
104 which we further identified five healthy phenotypes, including no usual insomnia complaints,
105 adequate sleep duration (7 to <9 hr/d), no snoring, morning chronotype, and no frequent daytime
106 sleepiness.(9) We scored participants from 0 to 5, according to the count of healthy
107 characteristics and categorized them into three groups: “healthy sleep” (≥ 4 composite sleep
108 score); “intermediate sleep” (2 or 3 score); and “poor sleep” (≤ 1 score). This categorization has
109 been proven to distinguish different CVD risk profiles, and the simple addition approach showed
110 a similar predictive power to a weighted score.(9) The original questions and options were
111 provided in **appendix pp 3**. These definitions and scores have shown excellent convergent
112 validity with CVD incidence and mortality.(8,9)

113

114 We identified recent clinical sleep disorder events (two years before enrolment) based on
115 inpatient admissions, primary care clinical events, and sleep disorder-specific prescriptions (BNF
116 Chapter 4 Section 1: hypnotics and anxiolytics). Modified from the definition provided by the
117 American Sleep Association and American Academy of Sleep Medicine,(16,17) we

118 distinguished five different sleep disorders, including insomnia, hypersomnia, sleep-related
119 breathing disorders, circadian rhythm sleep disorders, and parasomnias (including sleep-related
120 bruxism). In addition, we grouped hypersomnia, circadian rhythm sleep disorders, parasomnias,
121 non-specific sleep disorders (*e.g.*, “poor sleep pattern”), and sleep medication prescriptions
122 without a corresponding clinical event into “other sleep disorders.” We provided detailed codes
123 for each classification system in **appendix pp4-7**. Since the clinical diagnosis of sleep disorders
124 mainly refers to more than one self-reported sleep characteristic, we did not further integrate
125 both self-reported and clinically unhealthy sleep.

126

127 **Statistical analysis**

128 We set the follow-up from the UK Biobank enrollment to the date of death, inpatient or death
129 registry censoring, or the 81st birthday, whichever came first. To avoid overestimation, we
130 constrained the censoring age (τ restriction) at 81, corresponding to the oldest age of death in the
131 analyzed sample.(18) Considering the pathophysiological differences in CVD risks between
132 sexes,(19) we stratified all our models by sex. To evaluate the sex-specific CVD-free residual
133 lifetime of participants with different exposures, we applied continuous-time three-state Cox
134 Markov survival models.(20,21) All participants started with the CVD-free state and
135 subsequently either (a) maintained healthy until censored, (b) were diagnosed with the disease(s)
136 and lived until censored, (c) maintained healthy then deceased, or (d) were diagnosed with the
137 disease(s) then deceased. We estimated state-specific residual lifetime at age 40,(22) and
138 calculated the total and CVD-free years of life lost by comparing the marginal life expectancies
139 spent in a healthy state between the population with questionnaire-based poor/intermediate sleep
140 (exposure) and those with healthy sleep (reference), or between the population with each

141 diagnosed sleep disorder (exposure) and those without (reference). Based on *a priori* defined
142 directed acyclic graphs (**appendix pp 20**),(23) we selected the following potential covariates:
143 age, socioeconomic status, mental health issues, perceived health, body mass index (BMI),
144 economic activity, and shift work, cigarette smoking, alcohol consumption, diet quality,
145 discretionary screen time, and physical activity. The detailed definitions and the original
146 questions of covariates were provided in **appendix pp 8**. Models examining each self-reported
147 sleep characteristic or diagnosed sleep disorder were further mutually adjusted for the remaining
148 characteristics or disorders. For all the life expectancy estimations, we applied median/ mean
149 value for categorical/numerous covariates, and for estimations of each self-reported sleep
150 characteristic/clinical sleep disorder, the remaining characteristics or disorders were set to
151 healthy.

152
153 We obtained the 95% CIs for life expectancy estimations via nonparametric bootstrapping with
154 1000 iterations. All data were processed in SAS 9·4 (on secured local computers), and analyses
155 were performed on R 4·1·1 (on secured local computers) or R 4·0·4 (on the University of
156 Sydney's high performance computing cluster Artemis). To improve comparability, we repeated
157 all analyses with Fine-Gray sub-distribution hazards models, in which non-CVD death was
158 entered as a competing risk to incident CVD.(24) Covariates stayed the same as in the primary
159 analyses.

160

161 **Results**

162 We sequentially excluded participants with missing data in any of the five self-reported sleep
163 characteristics (n = 91802), with an inpatient or self-reported history of CVD (n = 54703), with
164 missing covariates (n = 32765), and with incident CVD or fatal events within the first two years
165 of follow-up (n = 14506), leaving 308683 participants for the core analysis of self-reported and
166 140181 participants for the clinically confirmed sleep events data (**Figure 1, appendix pp 9-11**).
167 Among the 308683 participants, with a mean follow-up of 11·8 (1·3) years from a mean age
168 56·2 (8·1), there were 13790 deaths from any cause and 53064 incident CVD, corresponding to
169 3653450 person-years at risk of death (**Table 1**). At baseline, 60% of the participants reported
170 healthy sleep, followed by 38% and 2% reporting intermediate and poor sleep, respectively
171 (**Table 1, appendix pp 12-13**). Participants who suffered from mental health problems,
172 perceived poor health, consumed a low-quality diet, had high BMI, faced higher socioeconomic
173 deprivation, retired, smoked/drank more, spent more discretionary time on screen, and exercised
174 less tended to have poor sleep in both sexes. Women were more likely to report healthy sleep
175 despite no appreciable differences in corresponding diagnoses (**appendix pp 14-15**).

176
177 At age 40, total life expectancy was an additional 39·07 [38·95-39·17] and 38·29 [38·16-38·41]
178 years (**appendix pp 16**), while CVD-free life expectancy was 33·05 [32·91-33·21] and 30·03
179 [29·88-30·20] years for females and males (**Table 2**). Although total life expectancy did not
180 differ between sleep groups (**Figure 2A, appendix pp 17**), there was a gradual decrease in
181 CVD-free life expectancy toward a higher number of self-reported sleep characteristics in both
182 sexes (**Table 2, Figure 2A**). Women with poor sleep had a CVD-free life expectancy of 31·46
183 [30·36-32·48] years, while those with healthy sleep had 33·26 [33·08-33·46] years (difference:
184 1·80 [0·96-2·75]). The Women's intermediate group lost 0·48 [0·41-0·55] life years (**Table 2,**

185 **Figure 3**). A similar pattern emerged among males, yet more pronounced than among women.
186 Poorly sleeping men expected a 27·96 [26·80-29·02] CVD-free life years, and healthy sleepers
187 had 30·27 [30·07-30·49] years (difference: 2·31 [1·46-3·29]). The composite sleep categories
188 suggested joint effects of different sleep characteristics compared to models only focusing on a
189 single characteristic (**Table 2, appendix pp 21**). The corresponding hazard ratios (HR) for CVD
190 were 1·13 [1·05-1·22] and 1·17 [1·09-1·26] in poor sleepers compared to healthy ones among
191 females and males (**appendix pp 22-25**).

192
193 Among the 140181 participants with primary care data available, 1203 had an insomnia
194 diagnosis in the last two years before their enrollment, while 2441 and 6489 were diagnosed with
195 sleep-related breathing disorders and other sleep disorders (**appendix pp14-15**). A confusion
196 matrix confirmed an assured negative predictive value of self-reported with diagnoses (**appendix**
197 **pp 18**). During an average follow-up of 11·8 (1·2) years and 1655597 person-years at risk of
198 death, 5996 died, and 23480 developed CVD. Total life expectancy was an additional 39·22
199 [39·05-39·37] and 38·29 [38·09-38·47] years (**Figure 2B, appendix pp 16**), while CVD-free life
200 expectancies were 33·37 [33·16-33·60] and 30·24 [30·01-30·50] years for females and males
201 (**Table 2, Figure 2B**). Contrary to self-report sleep, participants with any clinical sleep disorders
202 lost up to 1·16 [0·43-2·21] life compared to those without (**appendix pp 16**). Those diagnosed
203 with sleep disorders showed similar characteristics to those with poor self-reported sleep
204 (**appendix pp14-15**). Women diagnosed with sleep-related breathing disorders or other sleep
205 disorders lost 7·32 [5·33-10·34] (HR: 2·09 [1·87-2·35]) or 1·43 [0·2-3·29] (HR: 1·20 [1·08-
206 1·34]) CVD-free years of life compared to those without the corresponding diagnosis,
207 respectively (**Table 2, Figure 3, appendix pp 26-29**). In men, those with insomnia or sleep-

208 related breathing disorders expected a significant CVD-free life loss by 3·84 [0·61-8·59] (HR:
209 1·49 [1·23-1·80]) or 6·73 [5·31-8·48] (HR: 1·83 [1·68-1·99]) years, respectively. Complete
210 estimations of life expectancy and HRs were provided in the **appendix pp 16, 22-29**.

211

212 **Discussion**

213 To our knowledge, the current study provides the first comprehensive analyses of sleep measures
214 with life expectancy, utilizing cohort study data and primary care electronic health records to
215 identify sleep disorders. At 40 years of age, participants with self-reported poor sleep lost 1·8
216 and 2·3 years of life free of CVD in women and men, respectively, compared to those who
217 reported healthy sleep. The diagnosis of sleep-related breathing disorders was associated with the
218 largest loss of life years without diseases in both sexes, up to 7·3 years, while diagnosed
219 insomnia compromised life years in men by 3·8 years. Our findings strongly suggest that people
220 with either self-reported or diagnosed unhealthy sleep have less life expectancy free of CVD.

221

222 “Seven to 9 hours of good-quality sleep on a regular basis, with consistent bed and wake-up
223 times” is the only national (Canada) guideline on sleep,(3) based on a review of reviews on
224 duration and a *de novo* systematic review of the regularity/consistency and
225 chronotype/timing.(5,6) Although we could not address sleep regularity/consistency as it was
226 outside the scope of the UK Biobank questionnaires, aligned with this guideline, our finding
227 supported that sleep duration and chronotype impact CVD-free life expectancy in both sexes.
228 However, “sleep quality” is a poorly defined term encompassing various measures and
229 characteristics, so in the present study, we applied available CVD risk factors, including

230 insomnia complaints, snoring, and daytime sleepiness. Despite the controversial outcomes
231 between recent systematic reviews of insomnia,(25,26) our analyses showed that insomnia
232 impacted CVD-free life expectancy differently between sexes, as highlighted by the distinct
233 effects of self-reported complaints and clinical insomnia. Although we found no association of
234 self-reported/co-sleeper-reported snoring with life expectancy outcomes, clinical sleep-related
235 breathing disorders were found to compromise CVD-free life expectancy in both sexes by up to
236 7·3 years. Our results are consistent with those from the only existing review on topic ²⁶ and
237 suggest that women with frequent daytime sleepiness impacted the number of CVD-free years.
238 The absence of clinical diagnosis of excessive daytime sleepiness and the low prevalence (*i.e.*,
239 33 out of 140181 participants) of circadian rhythm sleep disorders, the corresponding clinical
240 diagnosis of chronotype, prohibited us from further investigating objective measurements.

241

242 Besides the independent effect of each characteristic, composite sleep measures provide more
243 comprehensive insights and a more coherent public health message(3) and are increasingly used
244 in cohort studies.(8,9) Although there is still no systematic review available on composite sleep
245 exposures, the present results, consistent with existing individual studies,(8,9) suggested that
246 people with multiple poor sleep characteristics had a shorter CVD-free year in both sexes. Our
247 study further suggested that this association is more prominent in males, while the very few
248 longitudinal results of sleep and health examining sex as an effect modifier are
249 incongruous.(6,27–29) The systematic review conducted by He et al. (2020) found that the
250 mortality risk of long sleep duration was higher in females, but the mortality risk of short sleep
251 was higher in males.(27) However, the systematic review of the Canadian national guideline and
252 recent prospective studies found no sex differences in the mortality and CVD risks of non-

253 adequate sleep duration.(6,28,29) Since capacities of sleep measurements vary between cohorts,
254 arbitrariness in the included sleep measures and the subsequent adjustments hamper the
255 aggregation of findings. More studies with detailed outcomes on each sleep measure are
256 warranted to facilitate future harmonization and consensus on essential sleep characteristics
257 selections.

258
259 This study's main strength and novelty is the use of primary care data linkage to identify sleep
260 disorders, allowing us to compare the differences between clinical sleep disorders and self-
261 reported poor sleep with detailed sleep questionnaires. The large sample size further allows us to
262 explore effect size with adequate statistical power. National hospitalization and death records
263 across all participants reduce the potential measurement bias of outcomes and allow us to
264 perform life expectancy analyses comprising morbidity and mortality. However, our study has
265 several limitations. First, sleep-related clinical events other than insomnia and sleep-related
266 breathing disorders were rare and thereby had to be grouped, compromising the specificity of our
267 analyses. Second, the UK Biobank has poor representativeness by oversampling the high
268 socioeconomic status, while our exclusion criteria further oversampled the healthy population
269 (**Appendix pp 9-11**), so our findings might not be generalizable to a population with different
270 socioeconomic status. The low prevalence of clinical sleep disorders also indicated a potential
271 underestimation due to the undiagnosed. However, recent UK Biobank evidence suggests that
272 poor representativeness is unlikely to influence the associations between lifestyle exposures and
273 mortality.(30) Third, we could not rule out immortal-time bias as the current analyses only
274 followed up mid-age healthy adults. Fourth, we could not distinguish CVD recovery and relapse
275 events based on available data, so we could not avoid overestimating the time spent on diseases.

276 Fifth, we only considered baseline measurements of exposures and covariates to maintain
277 statistical power, although our previous finding suggested a reasonable temporal consistency.(8)
278 Lastly, in the current study, we conservatively chose underlying conditions as covariables since
279 comorbidities could be on the causal pathway (*i.e.*, mediators). We could not eliminate the
280 potential residual confounding (**Appendix pp 20**), so the true causality could be biased.

281

282 **Conclusions**

283 In summary, this study provides further support for the advantage of a composite sleep score
284 based on easily applied self-reported questions. With access to primary care records, our findings
285 shed light on how clinical sleep disorders could be adversely associated with CVD-free life
286 expectancy. These results could lay the cornerstone for future research on early prevention
287 against poor sleep and improving CVD-free life expectancy among poor sleepers. Especially, we
288 hope that the current outcomes can serve as a reference for policymakers and professionals to
289 develop national sleep guidelines.

290

291 **List of Abbreviations**

292 BMI, Body Mass Index

293 BNF, British National Formulary

294 CTV3, Clinical Terms Version 3

295 CVD, Cardiovascular Disease

296 dm+d, Dictionary of Medicines and Devices

297 HR, Hazard Ratios

298 ICD, International Classification of Diseases

299 NHS, National Health Service

300 Read v2, Read codes version 2

301

302 **Declarations**

303 **Ethics approval**

304 This study was a secondary analysis of previously collected data so additional ethical approval
305 was not required. The National Health Service and the National Research Ethics Service have
306 approved the UK Biobank (Ref. 11/NW/0382) while all participants gave written informed
307 consent.

308 **Consent for publication**

309 Not applicable.

310 **Availability of data and materials**

311 The data that support the findings of this study are available from the UK Biobank but
312 restrictions apply to the availability of these data, which were used under license for the current
313 study, and so are not publicly available. Data are however available from the authors upon
314 reasonable request and with permission of the UK Biobank.

315 **Competing interests**

316 All authors declare no competing interests.

317 **Funding**

318 BH is a PhD student supported by the Taiwanese Ministry of Education and the University of
319 Sydney. ES is funded by the Australian National Health and Medical Research Council through
320 an Investigator Grant Level 2 (APP1180812). No conflict of interest was declared as the funding
321 sources had no involvement in the study design; in the collection, analysis, and interpretation of
322 data; in the writing of the report; or in the decision to submit the article for publication.

323 **Authors' contributions**

324 BH: conceptualization, software, formal analysis, visualization, writing – original draft. BPC &
325 AT: methodology, software, validation, writing – review & editing. PC: conceptualization,
326 methodology, writing – review & editing. ES: funding acquisition, project administration,
327 resources, supervision, writing – review & editing.

328 **Acknowledgements**

329 This research has been conducted using the UK Biobank Resource under Application Number
330 25813. The authors gratefully thank all the participants and professionals contributing to the UK
331 Biobank. In addition, the authors acknowledge the Sydney Informatics Hub and the Artemis
332 University of Sydney's high-performance computing cluster Artemis for providing the
333 computing resources and support to complete the research reported in this paper.

References

1. World Health Organization. Guidelines on physical activity, sedentary behaviour and sleep for children under 5 years of age [Internet]. World Health Organization; 2019 [cited 2021 Sep 23]. 33 p. Available from: <https://apps.who.int/iris/handle/10665/311664>
2. Baglioni C, Altena E, Bjorvatn B, Blom K, Bothelius K, Devoto A, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. *J Sleep Res* [Internet]. 2020 Apr [cited 2021 Sep 23];29(2). Available from: <https://onlinelibrary.wiley.com/doi/10.1111/jsr.12967>
3. Ross R, Chaput JP, Giangregorio LM, Janssen I, Saunders TJ, Kho ME, et al. Canadian 24-Hour Movement Guidelines for Adults aged 18–64 years and Adults aged 65 years or older: an integration of physical activity, sedentary behaviour, and sleep. *Appl Physiol Nutr Metab* [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S57–102. Available from: <https://cdnsiencepub.com/doi/10.1139/apnm-2020-0467>
4. Buysse DJ. Sleep Health: Can We Define It? Does It Matter? *Sleep* [Internet]. 2014 Jan 1 [cited 2022 Oct 9];37(1):9–17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902880/>
5. Chaput JP, Dutil C, Featherstone R, Ross R, Giangregorio L, Saunders TJ, et al. Sleep timing, sleep consistency, and health in adults: a systematic review. *Appl Physiol Nutr Metab* [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S232–47. Available from: <https://cdnsiencepub.com/doi/10.1139/apnm-2020-0032>
6. Chaput JP, Dutil C, Featherstone R, Ross R, Giangregorio L, Saunders TJ, et al. Sleep duration and health in adults: an overview of systematic reviews. *Appl Physiol Nutr Metab* [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S218–31. Available from: <https://cdnsiencepub.com/doi/10.1139/apnm-2020-0034>
7. Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. *Sleep Health J Natl Sleep Found* [Internet]. 2015 Mar 1 [cited 2020 Jan 31];1(1):40–3. Available from: [https://www.sleephealthjournal.org/article/S2352-7218\(15\)00015-7/abstract](https://www.sleephealthjournal.org/article/S2352-7218(15)00015-7/abstract)
8. Huang BH, Duncan MJ, Cistulli PA, Nassar N, Hamer M, Stamatakis E. Sleep and physical activity in relation to all-cause, cardiovascular disease and cancer mortality risk. *Br J Sports Med* [Internet]. 2022;56:718–24. Available from: [10.1136/bjsports-2021-104046](https://doi.org/10.1136/bjsports-2021-104046)
9. Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur Heart J* [Internet]. 2020 Mar 14 [cited 2020 Nov 11];41(11):1182–9. Available from: <http://academic.oup.com/eurheartj/article/41/11/1182/5678714>
10. Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. *The Lancet* [Internet]. 2019 Nov 16 [cited 2021 Jun 10];394(10211):1827–35. Available from: <https://www.sciencedirect.com/science/article/pii/S0140673619323165>
11. Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. *BMJ* [Internet]. 2020 Jan 8

- [cited 2021 Jun 10];368:16669. Available from: <https://www-bmj-com.ezproxy.library.sydney.edu.au/content/368/bmj.16669>
12. del Pozo Cruz B, Biddle SJH, Gardiner PA, Ding D. Light-Intensity Physical Activity and Life Expectancy: National Health and Nutrition Survey. *Am J Prev Med* [Internet]. 2021 Sep 1 [cited 2021 Aug 18];61(3):428–33. Available from: <https://www.sciencedirect.com/science/article/pii/S0749379721001768>
 13. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med* [Internet]. 2015 Mar 31 [cited 2020 Apr 28];12(3):e1001779. Available from: <https://dx.plos.org/10.1371/journal.pmed.1001779>
 14. Conroy M, Sellors J, Effingham M, Littlejohns TJ, Boulwood C, Gillions L, et al. The advantages of UK Biobank’s open-access strategy for health research. *J Intern Med* [Internet]. 2019 Oct 1 [cited 2021 Jul 10];286(4):389–97. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.12955>
 15. Zhao M, Veeranki SP, Magnussen CG, Xi B. Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. *BMJ* [Internet]. 2020 Jul 1 [cited 2020 Jul 4];370. Available from: <http://www.bmj.com/content/370/bmj.m2031>
 16. Authors ASA, Reviewers RP at ASA, physicians W certified sleep MD, scientists, editors, ASA writers for. Sleep Disorders ICD 10 Codes - Research & Treatments | American Sleep Assoc [Internet]. American Sleep Association. 2021 [cited 2021 Jun 11]. Available from: <https://www.sleepassociation.org/health-professionals/sleep-disorders-icd-10-codes-names/>
 17. Sateia MJ. International Classification of Sleep Disorders-Third Edition. *Chest* [Internet]. 2014 Nov 1 [cited 2021 Sep 1];146(5):1387–94. Available from: <https://www.sciencedirect.com/science/article/pii/S0012369215524070>
 18. Plana-Ripoll O, Canudas-Romo V, Weye N, Laursen TM, McGrath JJ, Andersen PK. lillies: An R package for the estimation of excess Life Years Lost among patients with a given disease or condition. *PLOS ONE* [Internet]. 2020 Mar 6 [cited 2021 Jun 10];15(3):e0228073. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228073>
 19. DeFilippis EM, Van SHGC. Is it Time for Sex-Specific Guidelines for Cardiovascular Disease? *J Am Coll Cardiol* [Internet]. 2021 Jul 13 [cited 2021 Jul 9];78(2):189–92. Available from: <https://www.jacc.org/doi/abs/10.1016/j.jacc.2021.05.012>
 20. van den Hout A. ELECT: Estimation of life expectancies using continuous-time multi-state survival models. ELECT Version 02 Vignette Ed2016. 2014;
 21. Jackson C. Multi-State Models for Panel Data: The msm Package for R. *J Stat Softw* [Internet]. 2011 Jan 4 [cited 2021 Sep 21];38(1):1–28. Available from: <https://www.jstatsoft.org/index.php/jss/article/view/v038i08>
 22. Nyberg ST, Batty GD, Pentti J, Virtanen M, Alfredsson L, Fransson EI, et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. *Lancet Public Health* [Internet]. 2018 Oct 1 [cited 2021 Jul 10];3(10):e490–7. Available from: [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(18\)30139-7/abstract](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30139-7/abstract)

23. Textor J, van der Zander B, Gilthorpe MS, Liškiewicz M, Ellison GTH. Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’ *Int J Epidemiol* [Internet]. 2017 Jan 15 [cited 2021 Sep 23];45(6):1887–94. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyw341>
24. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime Risks of Cardiovascular Disease. *N Engl J Med* [Internet]. 2012 Jan 26 [cited 2021 Nov 6];366(4):321–9. Available from: <https://doi.org/10.1056/NEJMoa1012848>
25. Ge L, Guyatt G, Tian J, Pan B, Chang Y, Chen Y, et al. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. *Sleep Med Rev* [Internet]. 2019 Dec 1 [cited 2020 Mar 11];48:101215. Available from: <http://www.sciencedirect.com/science/article/pii/S1087079219301753>
26. Lovato N, Lack L. Insomnia and mortality: A meta-analysis. *Sleep Med Rev* [Internet]. 2019 Feb 1 [cited 2020 Mar 11];43:71–83. Available from: <http://www.sciencedirect.com/science/article/pii/S1087079218300741>
27. He M, Deng X, Zhu Y, Huan L, Niu W. The relationship between sleep duration and all-cause mortality in the older people: an updated and dose-response meta-analysis. *BMC Public Health* [Internet]. 2020 Dec [cited 2022 Jan 26];20(1):1179. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09275-3>
28. Cao Z, Xu C, Yang H, Li S, Wang Y. The Role of Healthy Lifestyle in Cancer Incidence and Temporal Transitions to Cardiometabolic Disease. *JACC CardioOncology* [Internet]. 2021 Dec [cited 2022 Aug 27];3(5):663–74. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2666087321002593>
29. Yang L, Xi B, Zhao M, Magnussen CG. Association of sleep duration with all-cause and disease-specific mortality in US adults. *J Epidemiol Community Health* [Internet]. 2021 Jun [cited 2022 Aug 27];75(6):556–61. Available from: <https://jech.bmj.com/lookup/doi/10.1136/jech-2020-215314>
30. Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is Cohort Representativeness Passé? Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank. *Epidemiology* [Internet]. 2021 Mar [cited 2021 Apr 30];32(2):179–88. Available from: https://journals.lww.com/epidem/fulltext/2021/03000/is_cohort_representativeness_pass___poststratified.4.aspx

Figure Titles and Footnotes

Figure 1. The participants' exclusion flowchart

Abbreviations: CVD, cardiovascular diseases. The detailed missing pattern was provided in **appendix pp 16-18**.

Figure 2. Total and cardiovascular disease-free life expectancy at age 40 among participants with different (A) questionnaire-based composite sleep scores or (B) diagnosed sleep disorders

The results were adjusted for age, socioeconomic status, mental health issues, perceived health, body mass index (BMI), economic activity and shift work, cigarette smoking, alcohol consumption, diet quality, discretionary screen time, and physical activity. Full estimations of each life expectancy were provided in **appendix pp 14**.

Retired/not in the workforce	1651 (48)	26566 (43)	42105 (39)	70322 (41)	1180 (38)	18159 (33)	24779 (32)	44118 (33)	114440 (37)
Employed not in shift work	1417 (42)	29820 (48)	57847 (53)	89084 (51)	1381 (45)	29616 (53)	43483 (57)	74480 (55)	163564 (53)
Employed in night shift work	166 (5)	2501 (4)	3307 (3)	5974 (3)	325 (11)	4577 (8)	4505 (6)	9407 (7)	15381 (5)
Employed in day shift work	173 (5)	3079 (5)	4914 (5)	8166 (5)	186 (6)	3056 (6)	3890 (5)	7132 (5)	15298 (5)
Cigarette Smoking									
Never	1671 (49)	34819 (56)	68510 (63)	105000 (61)	1266 (41)	26288 (47)	41967 (55)	69521 (51)	174521 (57)
Cessation	1189 (35)	20647 (33)	32600 (30)	54436 (31)	1278 (42)	21370 (39)	27170 (35)	49818 (37)	104254 (34)
Current	547 (16)	6500 (10)	7063 (7)	14110 (8)	528 (17)	7750 (14)	7520 (10)	15798 (12)	29908 (10)
Alcohol Drinking									
Never	170 (5)	2892 (5)	5170 (5)	8232 (5)	64 (2)	1114 (2)	1791 (2)	2969 (2)	11201 (4)
Quit	175 (5)	2059 (3)	3051 (3)	5285 (3)	137 (4)	1522 (3)	2177 (3)	3836 (3)	9121 (3)
< 14 UK Units/wk	2178 (64)	40306 (65)	74036 (68)	116520 (67)	1175 (38)	21933 (40)	33350 (44)	56458 (42)	172978 (56)
14 to <28 UK Units/wk	553 (16)	11667 (19)	19728 (18)	31948 (18)	687 (22)	14793 (27)	21668 (28)	37148 (27)	69096 (22)
>= 28 UK Units/wk	331 (10)	5042 (8)	6188 (6)	11561 (7)	1009 (33)	16046 (29)	17671 (23)	34726 (26)	46287 (15)
Dietary Quality									
Poor	226 (7)	2535 (4)	3034 (3)	5795 (3)	491 (16)	6921 (12)	6730 (9)	14142 (10)	19937 (6)
Intermediate	2082 (61)	36714 (59)	61282 (57)	100078 (58)	2041 (66)	36785 (66)	50107 (65)	88933 (66)	189011 (61)
Healthy	1099 (32)	22717 (37)	43857 (41)	67673 (39)	540 (18)	11702 (21)	19820 (26)	32062 (24)	99735 (32)
Discretionary Screen Time (hr/d)	4.5 (2.6)	3.8 (2.0)	3.4 (1.8)	3.6 (1.9)	4.7 (2.6)	4.2 (2.2)	3.8 (2.0)	4.0 (2.1)	3.8 (2.0)
Physical Activity									
No MVPA	850 (25)	11686 (19)	15716 (15)	28252 (16)	729 (24)	8942 (16)	9287 (12)	18958 (14)	47210 (15)
< 10 MET hrs/wk	470 (14)	7131 (12)	10440 (10)	18041 (10)	382 (12)	6531 (12)	7354 (10)	14267 (11)	32308 (10)
10 to <20 MET hrs/wk	469 (14)	9779 (16)	17268 (16)	27516 (16)	427 (14)	8314 (15)	11144 (15)	19885 (15)	47401 (15)
>= 20 MET hrs/wk	1618 (47)	33370 (54)	64749 (60)	99737 (57)	1534 (50)	31621 (57)	48872 (64)	82027 (61)	181764 (59)

Data were shown in N (% vertically) or Mean (SD) for categorical or continuous variables, respectively. Abbreviations: CVD, cardiovascular diseases; MET, metabolic equivalent task; MVPA, moderate-to-vigorous physical activity. A summary without sex stratification was provided in **appendix pp 9-10**, and a characteristic table of participants with different diagnosed sleep disorders was provided in **appendix pp 11-12**.

Table 2. Cardiovascular-free life expectancy and years of life lost at age 40 among participants with different sleep exposures

Exposures	Females		Males	
	CVD-Free Life Expectancy	CVD-Free Years of Life Lost	CVD-Free Life Expectancy	CVD-Free Years of Life Lost
Total included participants	33·05 [32·91-33·21]	..	30·03 [29·88-30·20]	..
Primary Care Subsample	33·37 [33·16-33·60]	..	30·24 [30·01-30·50]	..
Sleep Characteristic*				
Usual Insomnia Complaints	32·98 [32·67-33·28]	0·30 [0·18-0·43]	30·09 [29·66-30·50]	0·14 [-0·05-0·35]
No Usual Insomnia Complaints	33·28 [33·07-33·47]	..	30·23 [30·01-30·45]	..
Inadequate Sleep Duration	32·63 [32·32-32·93]	0·63 [0·51-0·76]	29·86 [29·50-30·21]	0·32 [0·19-0·45]
Adequate Duration	33·26 [33·05-33·45]	..	30·18 [29·94-30·42]	..
Snoring	33·07 [32·76-33·37]	-0·01 [-0·08-0·06]	30·06 [29·80-30·32]	0·09 [0·00-0·17]
No Snoring	33·26 [33·06-33·45]	..	30·41 [30·16-30·66]	..
Evening Chronotype	33·21 [32·93-33·47]	0·19 [0·07-0·32]	30·20 [29·90-30·51]	0·35 [0·31-0·4]
Morning Chronotype	33·20 [32·99-33·39]	..	30·29 [30·05-30·52]	..
Frequent Daytime Sleepiness	32·33 [31·00-33·37]	0·92 [0·04-2·06]	29·85 [28·40-30·98]	0·41 [-0·55-1·66]
Infrequent Daytime Sleepiness	33·24 [33·06-33·41]	..	30·26 [30·05-30·46]	..
Composite Sleep Score†				
≤ 1	31·46 [30·36-32·48]	1·90 [1·10-2·76]	27·96 [26·80-29·02]	2·21 [1·48-3·07]
2	32·73 [32·27-33·19]	0·62 [0·41-0·85]	29·36 [28·86-29·86]	0·82 [0·61-1·02]
3	32·78 [32·51-33·09]	0·57 [0·5-0·65]	29·84 [29·57-30·15]	0·33 [0·21-0·45]
4	33·32 [33·09-33·58]	0·04 [-0·03-0·11]	30·30 [30·06-30·57]	-0·13 [-0·25-0·01]
5	33·36 [33·07-33·68]	..	30·17 [29·81-30·56]	..
Poor (≤ 1)	31·46 [30·36-32·48]	1·80 [0·96-2·75]	27·96 [26·80-29·02]	2·31 [1·46-3·29]
Intermediate (2 to 3)	32·77 [32·54-33·03]	0·48 [0·41-0·55]	29·72 [29·48-29·97]	0·55 [0·49-0·61]
Healthy (≥ 4)	33·26 [33·08-33·46]	..	30·27 [30·07-30·49]	..
Clinical Diagnosed Sleep Disorder*				
Insomnia	31·77 [28·23-33·78]	1·58 [-0·24-4·97]	26·32 [21·34-29·73]	3·84 [0·61-8·59]
Without This Condition	33·36 [33·11-33·57]	..	30·16 [29·92-30·39]	..
Sleep-Related Breathing Disorders	26·01 [22·80-28·21]	7·32 [5·33-10·34]	23·48 [21·54-25·10]	6·73 [5·31-8·48]
Without This Condition	33·34 [33·09-33·56]	..	30·21 [29·96-30·44]	..
Other Sleep Disorders	31·91 [29·81-33·34]	1·43 [0·20-3·29]	29·19 [27·11-30·77]	0·99 [-0·36-2·85]
Without This Condition	33·33 [33·09-33·55]	..	30·18 [29·93-30·41]	..
With Any Sleep Disorders	30·64 [29·46-31·74]	2·73 [1·85-3·72]	26·46 [25·30-27·58]	3·79 [2·89-4·71]
Without Any Sleep Disorders	33·37 [33·16-33·60]	..	30·24 [30·01-30·50]	..

Data were shown in estimation [95% CI], with values in bold denoting statistical significance. For all the estimations, we applied median or mean value for categorical or numerous covariates, respectively, and for estimations of each self-reported sleep characteristic or each diagnosed sleep disorder, the remaining characteristics or disorders were set to healthy. *Compared to those without poor sleep characteristics/diagnosed conditions. †Compared to the healthiest group (five score/healthy group). Full estimations of each life expectancy were provided in **appendix pp 14**. Abbreviations: CVD, cardiovascular diseases.

N = 502,459
in the present UK Biobank dataset

Self-Reported Sleep

Primary Care Records

N = 502,459
in the present UK Biobank dataset

N = 227,834
with primary care data linkage

N = 91,802
with missing data in the five
self-reported sleep variables.

N = 11,795
with systematic errors:
Events before born (n= 24);
Events at the year born (n=
9428);
Events in the future (n= 2523).

N = 410,657
with usable self-reported sleep

N = 216,039
without systematic registry error

N = 54,703
with inpatient hospitalization or
self-reported history of CVD.

N = 2,767
with potentially non-systematic
error (*i.e.*, disease date earlier
than registration date)

N = 355,954
without previous disease history

N = 213,272
with usable primary care data

N = 32,765
with missing data in covariates.

N = 323,189
with full data of selected variables


N = 14,506
with fatal events within the first
two years of follow-up.

N = 308,683
included in the analyses
based on the self-reported


N = 140,181
included in the analyses
based on primary care and
inpatient records

→

Females



Males




Life expectancy with CVD
CVD-free life expectancy

Life Expectancy at age 40

Questionnaire-Based Composite Sleep Scores

Females



Males

